Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Fernando Cabanillas, Auxilio Mutuo Cancer Center
ClinicalTrials.gov Identifier:
NCT01538641
First received: February 21, 2012
Last updated: July 11, 2012
Last verified: July 2012

February 21, 2012
July 11, 2012
October 2003
August 2007   (final data collection date for primary outcome measure)
The response rate of the combination of Gemcitabine-Oxaliplatin-Rituximab. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01538641 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas
Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

Study Proposal:

Other drugs where synergy with Gemcitabine has been observed are Cisplatinum, Taxol, Taxotere, Etoposide and alkylating agents. However in view of Oxaliplatin's superior activity as a single agent against lymphoma, the combination of Gemcitabine with Oxaliplatin is more attractive and should be explored in this group of disorders. Based on these data and considering the advantage of its favorable toxicity profile, we propose a phase II study in patients with either refractory or relapsing aggressive non-Hodgkin's lymphomas including peripheral T-cell lymphomas which are known to have a poor outcome when compared with equivalent aggressive B-cell lymphomas.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Refractory Aggressive Non-Hodgkin's Lymphoma
  • Relapsing Aggressive Non-Hodgkin's Lymphoma
Drug: Rituximab, Gemcitabine, Oxaliplatin
Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
Experimental: 1
Intervention: Drug: Rituximab, Gemcitabine, Oxaliplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
43
December 2008
August 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with refractory or relapsed aggressive non-Hodgkin's Lymphoma. The definition of refractory includes patients who either did not respond to prior therapy or those whose best response was a PR after at least 4 courses of chemotherapy. Aggressive histologies include follicular large cell, diffuse large cell, peripheral T cell, transformed lymphomas, Lymphoblastic lymphomas, Burkitt and Burkitt like lymphomas.
  • Histologic or cytological confirmation of refractory or relapsed aggressive non-Hodgkin's Lymphoma is desirable but not mandatory and will be left to the discretion of the investigator.
  • Must have measurable or evaluable disease.
  • No more than 4 previous regimens of chemotherapy will be allowed, including stem cell or bone marrow transplant.
  • Patients must be more than 18 years old.
  • No evidence of grade 3 or more neurosensory or neuromotor dysfunction (see appendix- toxicity criteria)
  • Written Consent
  • Those patients who have previously received a platinum or nucleoside analogue-containing regimen are eligible.
  • Patients who are candidates for stem cell or marrow transplant will be included

Exclusion Criteria:

  • Patients with a previous or concurrent history of cancer with the exception of: 1-treated carcinoma in situ of cervix or breast. 2- treated squamous or basal cell skin cancer, or 3- any other surgically cured malignancy from which the patient has been disease free for at least 5 years.
  • HIV positive patients and those with Hepatitis B or C will be excluded from this protocol.
  • Patients with severe neuropathy will be excluded.
  • Chemotherapy or Radiotherapy within the previous 3 weeks prior to entering study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01538641
CCAM-03-01
Yes
Fernando Cabanillas, Auxilio Mutuo Cancer Center
Auxilio Mutuo Cancer Center
Not Provided
Not Provided
Auxilio Mutuo Cancer Center
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP